Ho Julie, Gibson Ian W, Zacharias James, Fervenza Fernando, Colon Selene, Borza Dorin-Bogdan
Section of Nephrology, University of Manitoba, Winnipeg, Manitoba, Canada.
Am J Kidney Dis. 2008 Oct;52(4):761-5. doi: 10.1053/j.ajkd.2008.03.041. Epub 2008 Aug 26.
Anti-glomerular basement membrane (anti-GBM) disease is an aggressive form of glomerulonephritis, usually mediated by immunoglobulin G (IgG) autoantibodies to the noncollagenous (NC1) domain of alpha 3(IV) collagen. Less is known about the target antigen(s) in patients with atypical anti-GBM disease involving IgA autoantibodies. We report a new case of IgA anti-GBM disease in a patient with a history of proliferative lupus nephritis who presented with increasing creatinine levels, proteinuria, and hematuria, but no clinical or serological evidence of lupus recurrence. Renal biopsy showed focal and segmental necrotizing glomerulonephritis with strong linear capillary loop IgA staining by means of immunofluorescence. Serological test results were negative for IgG or IgA autoantibodies against the alpha 3NC1 domain. By means of immunoblotting, IgA from patient serum bound to 38- to 48-kd antigens collagenase-solubilized from human GBM, but not to purified NC1 domains of GBM collagen IV. The target of patient's IgA autoantibodies thus was identified as a novel GBM antigen, distinct from the alpha 3NC1 domain or other known targets of anti-GBM IgA autoantibodies. Clinical resolution was attained by means of conventional treatment with steroids and cyclophosphamide. The diversity of antigens recognized by anti-GBM IgA autoantibodies highlights the importance of renal biopsy for the reliable diagnosis of this rare condition because conventional serological immunoassays likely would yield false-negative results.
抗肾小球基底膜(anti-GBM)病是一种侵袭性肾小球肾炎,通常由针对α3(IV)型胶原非胶原(NC1)结构域的免疫球蛋白G(IgG)自身抗体介导。对于涉及IgA自身抗体的非典型抗GBM病患者的靶抗原了解较少。我们报告了一例IgA抗GBM病的新病例,患者有增殖性狼疮性肾炎病史,表现为肌酐水平升高、蛋白尿和血尿,但无狼疮复发的临床或血清学证据。肾活检显示局灶性节段性坏死性肾小球肾炎,免疫荧光检查显示毛细血管袢有强烈的线性IgA染色。血清学检测结果显示,针对α3NC1结构域的IgG或IgA自身抗体均为阴性。通过免疫印迹法,患者血清中的IgA与从人肾小球基底膜胶原酶溶解的38至48kd抗原结合,但不与肾小球基底膜IV型胶原的纯化NC1结构域结合。因此,患者IgA自身抗体的靶抗原被确定为一种新型肾小球基底膜抗原,不同于α3NC1结构域或抗GBM IgA自身抗体的其他已知靶抗原。通过使用类固醇和环磷酰胺的传统治疗实现了临床缓解。抗GBM IgA自身抗体识别的抗原多样性突出了肾活检对可靠诊断这种罕见疾病的重要性,因为传统的血清学免疫测定可能会产生假阴性结果。